Please login to the form below

Not currently logged in
Email:
Password:

Symdeko

This page shows the latest Symdeko news and features for those working in and with pharma, biotech and healthcare.

Vertex scores FDA approval for CF triple therapy Trikafta

Vertex scores FDA approval for CF triple therapy Trikafta

and Symkevi/Symdeko (tezacaftor/ivacaftor) – which can treat around half of patients. ... The list price of $311, 000 is more than Leerink analyst Geoffrey Porges' prediction that the triple therapy could be priced similarly to Symdeko, which costs $233

Latest news

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics